The latter approach is essentially forward stepwise, which is more appropriate for situations where one or more pathways are distinctly characterized by dysregulation of one or a few genes (e.g. FGFR3 and MMSET in t(4;14) multiple myeloma [33]). Here, NSD2 is linked to plasma cell myeloma.